MNG1267
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.273
- E2F_TARGETS+0.261
- G2M_CHECKPOINT+0.251
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.232
- MYC_TARGETS_V2+0.223
- GLYCOLYSIS+0.186
- CHOLESTEROL_HOMEOSTASIS+0.185
- SPERMATOGENESIS+0.176
- KRAS_SIGNALING_DN+0.147
- ESTROGEN_RESPONSE_LATE+0.141
Top 10 suppressed
- TGF_BETA_SIGNALING-0.484
- PROTEIN_SECRETION-0.417
- UV_RESPONSE_DN-0.378
- ANDROGEN_RESPONSE-0.361
- TNFA_SIGNALING_VIA_NFKB-0.312
- INTERFERON_ALPHA_RESPONSE-0.252
- HEME_METABOLISM-0.232
- MYC_TARGETS_V1-0.228
- FATTY_ACID_METABOLISM-0.210
- WNT_BETA_CATENIN_SIGNALING-0.195
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A2-A3XS-01A-11R-A22U-07 | — | E | 0.717 |
| 2 | TCGA-NK-A7XE-01A-12R-A405-07 | — | cohortSQ1 | 0.698 |
| 3 | R233 | — | — | 0.677 |
| 4 | TCGA-BH-A0E6-01A-11R-A034-07 | — | E | 0.674 |
| 5 | SRR1797263 | — | cohortSC | 0.673 |
| 6 | SRR12202407 | — | — | 0.673 |
| 7 | TCGA-60-2726-01A-01R-0851-07 | — | cohortSQ1 | 0.670 |
| 8 | SRR650168 | — | — | 0.670 |
| 9 | AUR-AFR5-TTM1-A-1-1-R-A743-41 | — | E | 0.670 |
| 10 | MNG192 | — | — | 0.669 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.273 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.261 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.251 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.232 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.223 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.186 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.185 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.176 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.147 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.141 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.080 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.060 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.028 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.024 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.013 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.004 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.004 | Idelalisib | — uncovered |